Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States
Overall, among adults with underlying medical conditions, mRNA-1273.222 was more effective than BNT162b2 Bivalent, especially in preventing COVID-19-related hospitalizations.
Authors
- James A. Mansi (ORCID: https://orcid.org/0000-0001-7650-6778)
- Alina Bogdanov (ORCID: https://orcid.org/0000-0001-9581-4194)
- Isabelle Winer (ORCID: https://orcid.org/0000-0002-7294-8162)
- Daina B. Esposito (ORCID: https://orcid.org/0000-0003-2894-0523)
- Thiérry Ducruet (ORCID: https://orcid.org/0000-0002-6013-1753)
- Cathérine Boileau (ORCID: https://orcid.org/0000-0002-0371-7539)
- Jessamine Winer‐Jones (ORCID: https://orcid.org/0000-0002-6412-4139)
- Mary T. Bausch-Jurken (ORCID: https://orcid.org/0000-0003-2386-7291)
- Ekkehard Beck
- Machaon Bonafede (ORCID: https://orcid.org/0000-0001-6330-6718)
- Hagit Kopel
- Văn Hùng Nguyễn (ORCID: https://orcid.org/0000-0001-5318-2416)
- Ni Zeng (ORCID: https://orcid.org/0000-0003-2368-5279)
Institutions
- SNC-Lavalin (Canada) (CA)
- Moderna Therapeutics (United States) (US)
Publication Details
- Journal
- Vaccines
- Published
- 2024-09-27
- DOI
- https://doi.org/10.3390/vaccines12101107
- Citations
- 11
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 4.28